1. Turmeric
The bitter yellow root — curcuminoids, microbiome, and clinical reality.
Turmeric in 1 minute
What does it provide? Curcuminoids (hydrophobic polyphenols — the source of the yellow color) and essential-oil terpenes. Curcumin's plasma absorption by itself is < 1%, so most of the effect is mediated by the colonic microbiome (which converts it to tetrahydrocurcumin and phenolic acids); it increases the proportion of Faecalibacterium prausnitzii and Bifidobacterium.[2234] Robust human RCT evidence: knee osteoarthritis pain reduction (Daily 2016 meta-analysis)[2230], maintenance of remission in ulcerative colitis alongside 5-ASA (Hanai 2006)[2231], NAFLD liver enzyme improvement.[2232]
How much? In the kitchen: ½–1 tsp (≈ 1–3 g) freshly ground rhizome/day, with a pinch of black pepper (piperine → 20× bioavailability increase, Shoba 1998)[2228] and fat (olive, ghee, coconut). Clinical supplement: 250–1000 mg curcuminoid/day, phospholipid or nano formulation.
When to avoid? Gallstone/bile duct obstruction/active cholangitis (choleretic effect — EMA contraindication)[2227]; active hepatitis or unexplained liver enzyme elevation (Italian pharmacovigilance 2018–2019: cluster of cholestatic hepatitis from piperine-containing supplements); anticoagulant therapy (warfarin/DOAC/clopidogrel — additive bleeding); 2 weeks before planned surgery (clinical-dose supplement). Detailed condition-specific contraindications (CYP3A4 interaction, pregnancy, iron deficiency) are in the detailed section.
Turmeric has been part of South Asian cuisine and medicinal tradition for more than 2,000 years: Indian Ayurveda regards it as a sacred spice under the name "haridra," and a foundational element of every Hindu wedding is the "haldi" ceremony, in which the bride's and groom's bodies are anointed with turmeric paste as a symbol of purification and fertility. Marco Polo described it as "Indian saffron" in his chronicle in the 13th century, and in the colonial era it became known worldwide with the global spread of "curry powder." Active-substance research began in 1815, when Vogel and Pelletier first isolated curcumin's yellow pigment, and Milobedzka clarified the chemical structure in 1910.
From the mid-20th century, curcumin research exploded: after the description of NF-κB inhibition, COX modulation, and antioxidant activity, several thousand publications examined it in clinical indications. European regulation (EMA/HMPC) limits medicinal claims to traditional digestive indications, but it has become one of the world's most popular dietary supplements. The Italian pharmacovigilance of 2018–2019, however, gave a warning sign: after high-dose curcumin supplements taken in combination with piperine (black pepper), a cluster of cholestatic hepatitis cases was registered — the "more = better" approach is therefore not safe.[2233]
Scientific Background
Curcuminoids are hydrophobic polyphenols whose plasma absorption alone is very poor (< 1%). The majority of the intake passes through the small intestine intact, and the colonic microbiome converts it — to tetrahydrocurcumin, dihydrocurcumin, and smaller phenolic acids. This explains why the relationship between systemic plasma level and clinical effect is weak, yet gut barrier and inflammation markers still change: most of the effect operates within the colon, via the microbiota.
The most stable human evidence is available for osteoarthritis (knee, hand), maintenance of ulcerative colitis (adjunctive to 5-ASA), and NAFLD, with moderate effect size. Bioavailability is dramatically increased by piperine (≈ 2000% exposure increase, Shoba 1998) and by phospholipid formulations (≈ 30× plasma level, Cuomo 2011)[2229].
At the microbiome level, human data show that regular curcumin consumption increases the proportions of Faecalibacterium prausnitzii and Bifidobacterium, while reducing the proportion of opportunistic Enterobacteriaceae. The effect strongly depends on baseline microbiota composition.
- + Black pepper (piperine): about 20× bioavailability increase in a classic human study. In the kitchen, ¼ tsp of freshly ground pepper to 1 tsp of turmeric. With clinical-dose supplements, caution (interaction, hepatotoxicity).
- + Healthy fat (extra virgin olive oil, coconut fat, ghee): curcumin is fat-soluble — consumption together increases its bioavailability. The Indian "tarka" (spice crackled in oil) tradition exploits exactly this.
- + Ginger: combined protective effect in osteoarthritis (several RCTs). The combination of the two rhizomes is the basis of the classic "golden milk."
- + Fiber-rich diet (legumes, whole grains, vegetables): most of the curcumin reaches the colon → fiber fermentation + curcumin metabolism = synergistic microbiome effect.
- + Yogurt/kefir (live cultures): support for the bacteria involved in curcumin metabolism.
- + Vitamin C-rich matrix (lemon, tomato): antioxidant synergy, polyphenol stabilization.
- Anticoagulants (warfarin, DOACs — apixaban, rivaroxaban, dabigatran, edoxaban; aspirin, clopidogrel): curcumin is antiplatelet and weakly anticoagulant — additive bleeding risk. Clinical-dose supplement to be avoided; culinary amount is safe.
- CYP3A4 substrates combined with piperine (statins, calcium-channel blockers, immunosuppressants — tacrolimus, cyclosporine; some antiretrovirals): piperine is a CYP3A4 inhibitor — drug level elevation possible.
- Iron supplementation: curcumin has chelating activity (Fe³⁺ binding) — separate the turmeric supplement and iron supplementation in time (≥ 2 hours).
- Hepatotoxic medications (paracetamol in high doses, methotrexate, isoniazid, amiodarone, statin) + high-dose curcumin supplement: additive hepatic stress.
- NSAIDs in high doses + curcumin: GI bleeding risk together.
- On an empty stomach, high-dose supplement: gastric irritation, reflux.
- Gallstone, active bile duct disease, cholangitis, bile duct obstruction: curcumin is choleretic (bile-flow-enhancing) → risk of colic attack, pain. The EMA monograph contraindicates it.
- Active hepatitis, unexplained liver enzyme elevation: Italian pharmacovigilance (2018–2019) documented a cluster of cholestatic hepatitis alongside piperine-containing supplements. In case of jaundice, dark urine, itching, immediate discontinuation and medical visit.
- Pregnancy (high dose): uterine-stimulating and emmenagogue potential in animal experiments. Culinary dose is safe; clinical-dose supplement not recommended.
- Breastfeeding: little human data on supplement doses; culinary amount acceptable.
- 2 weeks before planned surgery: stop high-dose supplement (bleeding risk).
- Kidney stone, particularly predisposition to calcium oxalate stones: turmeric's oxalate content is moderate-to-high; clinical-dose supplement to be avoided.
- Active gastric ulcer, reflux disease flare: GI irritation possible at high doses.
- Iron-deficiency anemia under treatment: curcumin can chelate iron.
- Asteraceae/Zingiberaceae allergy: rare, but cross-reactivity possible.
Daily serving
½–1 teaspoon (≈ 1–3 g) of freshly ground turmeric rhizome.
Preparation pattern
- In a hot pan, 1 tbsp oil (olive/coconut/ghee), 30 seconds.
- ½–1 tsp turmeric + ¼ tsp freshly ground black pepper → 20–30 sec crackling.
- Add to vegetables/legumes/meat toward the end of cooking (NOT at the beginning — long, high-temperature heating degrades curcuminoids).
Classic patterns
Dal: red lentils + turmeric + ginger + pepper + ghee — the best-documented, "every ingredient synergistic" pattern.
Golden milk: plant milk (coconut, almond) + turmeric + pepper + ginger + a little honey — evening, warming, before bed.
Yellow curry: turmeric + coconut milk + vegetables + bean — gluten- and dairy-free base.
Turmeric rice: ½ tsp turmeric in the cooking water of long-grain rice — simple daily fiber+polyphenol combination.
Storage and what to avoid
Storage: in an airtight glass jar, in a dark place — curcuminoids are light-sensitive. Fresh rhizome in the fridge max. 2 weeks; frozen 6 months.
What not to do: don't overcook (≥ 100 °C, 30+ minutes) — curcuminoid loss. Don't arbitrarily combine clinical-dose curcumin supplements with piperine.
References
[2227] EMA/HMPC 2018 (rev. EMA/HMPC 2018 (rev. 1). Community herbal monograph on Curcuma longa L., rhizoma. 2018.
EMA/HMPC community herbal monograph (2018, rev. 1) on Curcuma longa L., rhizoma (turmeric rhizome).
[2228] Shoba G et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers1998;64(4):353–356. Planta Medica. Link
The medicinal properties of curcumin obtained from Curcuma longa L. cannot be utilised because of poor bioavailability due to its rapid metabolism in the liver and intestinal wall. In this study, the effect of combining piperine, a known inhibitor of hepatic and intestinal glucuronidation, was evaluated on the bioavailability of curcumin in rats and healthy human volunteers. When curcumin was given alone, in the dose 2 g/kg to rats, moderate serum concentrations were achieved over a period of 4 h. Concomitant administration of piperine 20 mg/kg increased the serum concentration of curcumin for a short period of 1-2 h post drug. Time to maximum was significantly increased (P < 0.02) while elimination half life and clearance significantly decreased (P < 0.02), and the bioavailability was increased by 154\%. On the other hand in humans after a dose of 2 g curcumin alone, serum levels were either undetectable or very low.
[2229] Cuomo J et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation2011;74(4):664–669. J Nat Prod. Link
The relative absorption of a standardized curcuminoid mixture and its corresponding lecithin formulation (Meriva) was investigated in a randomized, double-blind, crossover human study. Clinically validated dosages were used for both products, and plasma levels of all three major curcuminoids [curcumin (1a), demethoxycurcumin (1b), and bisdemethoxycurcumin (1c)] were evaluated. Total curcuminoid absorption was about 29-fold higher for Meriva than for its corresponding unformulated curcuminoid mixture, but only phase-2 metabolites could be detected, and plasma concentrations were still significantly lower than those required for the inhibition of most anti-inflammatory targets of curcumin. Remarkably, phospholipid formulation increased the absorption of demethoxylated curcuminoids much more than that of curcumin (1a), with significant differences in plasma curcuminoid profile between Meriva and its corresponding unformulated curcuminoid mixture. Thus, the major plasma curcuminoid after administration of Meriva was not curcumin (1a), but demethoxycurcumin (1b), a more potent analogue in many in vitro anti-inflammatory assays. The improved absorption, and possibly also a better plasma curcuminoid profile, might underlie the clinical efficacy of Meriva at doses significantly lower than unformulated curcuminoid mixtures.
[2230] Daily JW et al. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis2016;19(8):717–729. J Med Food. Link
Systematic review and meta-analysis (J Med Food) on the efficacy of turmeric extracts and curcumin for alleviating joint arthritis symptoms.
[2231] Hanai H et al. Curcumin maintenance therapy for ulcerative colitis2006;4(12):1502–1506. Clin Gastroenterol Hepatol. Link
BACKGROUND \& AIMS: Curcumin is a biologically active phytochemical substance present in turmeric and has pharmacologic actions that might benefit patients with ulcerative colitis (UC). The aim in this trial was to assess the efficacy of curcumin as maintenance therapy in patients with quiescent ulcerative colitis (UC). METHODS: Eighty-nine patients with quiescent UC were recruited for this randomized, double-blind, multicenter trial of curcumin in the prevention of relapse. Forty-five patients received curcumin, 1g after breakfast and 1g after the evening meal, plus sulfasalazine (SZ) or mesalamine, and 44 patients received placebo plus SZ or mesalamine for 6 months. Clinical activity index (CAI) and endoscopic index (EI) were determined at entry, every 2 months (CAI), at the conclusion of 6-month trial, and at the end of 6-month follow-up. RESULTS: Seven patients were protocol violators.
[2232] Ebrahimzadeh A et al. Curcumin in NAFLD: meta-analysis of randomized controlled trials 2025. Phytother Res. 2025.
Meta-analysis of randomized controlled trials (Phytother Res, 2025) on the effect of curcumin in non-alcoholic fatty liver disease (NAFLD).
[2233] Italian National Institute of Health (ISS). Hepatitis from curcumin/piperine supplements — pharmacovigilance report 2020. . 2020.
Pharmacovigilance report by the Italian National Institute of Health (ISS, 2020) on hepatitis cases associated with curcumin/piperine supplements.
[2234] Scazzocchio B et al. Interaction between gut microbiota and curcumin: a new key of understanding for the health effects of curcumin2020;12(9):2499. Nutrients. Link
Review (Nutrients, 2020) on the interaction between gut microbiota and curcumin as a key to understanding curcumin's health effects.
[2235] EFSA. Refined exposure assessment for curcumin (E100) 2014. EFSA Journal. 2014.
EFSA refined exposure assessment (EFSA Journal, 2014) for curcumin (E100) as a food additive.